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Once-vs Twice-Daily Budesonide/Formoterol in 6-to 15-Year-Old Patients With Stable Asthma Current asthma management guidelines recommend the combination of an inhaled corticosteroid (ICS) and a long-acting ␤ 2 -adrenergic agonist (LABA) as a preferred treatment for patients aged 5 years and older with asthma that is not controlled with an ICS alone. 1 Recommendations also include using the least amount of pharmacologic agents necessary to control asthma. 1 Once-daily dosing of budesonide/formoterol dry powder inhaler (DPI) (Symbicort Turbuhaler [AstraZeneca, Lund, Sweden] ) has shown significantly better results for asthmacontrol variables versus a fourfold higher dose of once-daily budesonide alone in 4-to 11-year-old asthmatic children. 2 Once-and twice-daily budesonide/formoterol DPI administered at the same daily doses of budesonide and formoterol have yielded similar results for asthma-control and pulmonary-function variables in adults with asthma. 3, 4 Once-daily budesonide/ formoterol administered via pressurized metered-dose inhaler (pMDI) (Symbicort Inhalation Aerosol [AstraZeneca LP, Wilmington, DE]) has shown better maintenance of asthma control and pulmonary function during 12 weeks versus once-daily budesonide monotherapy at the same daily budesonide dose in patients aged 12 years and older with mild-to-moderate persistent asthma that was previously stabilized with twice-daily budesonide/ formoterol pMDI. 5 Better asthma control, however, was shown with twicedaily budesonide/formoterol dosing versus once-daily budesonide/formoterol at half the daily formoterol dose, and there was no evident safety benefit for once-daily dosing.
The primary objective of this study was to assess the efficacy and tolerability of once-daily budesonide/formoterol via pMDI compared with the same dose of once-daily budesonide via pMDI in children and adolescents aged 6 to 15 years with asthma that was previously stable with twice-daily budesonide/ formoterol pMDI. This comparison permitted assessment of formoterol's contribution to once-daily budesonide/ formoterol pMDI therapy. Secondary objectives were to assess the efficacy of remaining on twice-daily budesonide/formoterol pMDI versus stepping down to once-daily budesonide/ formoterol pMDI at half the daily formoterol dose or once-daily budesonide via pMDI alone.
METHODS

Patients
At screening, patients aged 6 to 15 years with a documented asthma diagnosis 6 for Ն6 months, stable disease based on consistent previous therapy, a prebronchodilator forced expiratory volume in 1 second (FEV 1 ) of 60% to 90% of predicted normal, and bronchodilator reversibility of Ն12% and Ն0.20 L in FEV 1 (Ն12% alone for patients younger than 11 years) were eligible for enrollment. Patients had mild-tomoderate asthma, which was based on ICS use (low-to-medium doses 7 for Ն4 weeks) and pulmonary function at screening.
Exclusion criteria included severe asthma or asthma that required treatment with systemic corticosteroids Յ1 month before screening, current smoking, a Ͼ10 pack-year smoking history, any significant confounding disease or disorder, or hypersensitivity to ␤ 2 -adrenergic agonists, budesonide, formoterol, or any excipients of the product formulation.
This study was approved by multiple institutional review boards. Written, informed consent from the parent/ guardian and assent from the child were obtained before any study procedures were performed.
Study Design and Treatment
In this 12-week, multicenter (95 US centers), double-blind, parallelgroup, active-controlled, randomized study (www.clinicaltrials.gov identifier NCT00646321; www.astrazeneca clinicaltrials.com identifiers SD-039-0725 and D5896C00725) conducted from January 29, 2003, to August 12, 2004 , patients who met eligibility criteria discontinued current therapy and received budesonide/formoterol pMDI 40/4.5 g ϫ 2 inhalations twice daily (160/18 g daily) and as-needed rescue albuterol during a 4-to 5-week run-in period. To be eligible for randomization, patients had to have stable asthma and a predose FEV 1 of Ͼ75% of predicted normal ϳ12 hours after the last dose of run-in treatment. Patients' asthma was considered stable if, during a consecutive 7-day period after 3 weeks of run-in therapy, the following criteria were met: symptom score of Յ1 (on a scale of 0 [no symptoms] to 3 [severe symptoms]) for Ն5 days, no daytime or nighttime symptom scores of 3, cumulative daytime-plusnighttime symptom scores of Յ12, and Յ2 nighttime asthma awakenings.
After the run-in period, eligible patients were stratified according to age at screening (6 -11 or 12-15 years) and randomly assigned to receive 1 of 3 treatments (see Fig 1) 1:1:1 in balanced blocks of size 3 within each age stratum at each center via a computergenerated randomization scheme produced centrally in advance. Patients who were assigned to receive oncedaily treatments administered placebo pMDI in the morning and active product in the evening with identical delivery devices to maintain study blinding.
Follow-up clinic visits occurred at weeks 2, 6, and 12 after randomization. Patients had to have Ն1 evening visit during the study to assess trough FEV 1 levels (after ϳ20 -24 hours for the e566once-daily treatments and after ϳ11-13 hours for twice-daily budesonide/formoterol pMDI). Patients who met any predefined criteria for worsening asthma were required to be withdrawn automatically from the study (Table 1) .
Concomitant Medications
Albuterol pMDI was provided as rescue medication. Treatment with systemic corticosteroids, dermatologic corticosteroids at a concentration of Ͼ1%, routine nebulized albuterol, hydroxyzine, or ␤-blockers and initiation of immunotherapy were not allowed during the study. Continuation of treatment with nasal corticosteroids was permitted if treatment began before screening. The use of a spacer device for the administration of study or rescue medication was not permitted.
Efficacy Evaluations
The primary efficacy variable was evening peak expiratory flow (PEF), which was chosen to assess the efficacy of once-daily budesonide/formoterol via pMDI 20 to 24 hours after taking the previous evening's dose of study medication (trough levels) and Ն6 hours after taking rescue medication. Patients (or caregivers) recorded the highest of 3 PEF measurements in an electronic diary (Logpad [PHT Corporation, Charlestown, MA]). Secondary efficacy variables recorded by patients in the electronic diaries included morning PEF, daytime and nighttime asthma symptom scores (0 [no symptoms] to 3 [severe symptoms]), nighttime awakenings attributable to asthma, and daytime and nighttime rescue-medication use (number of inhalations). Diary data were applied to predefined criteria for worsening asthma (Table 1 ) on a daily basis by using a 7-day rolling window. Events of worsening asthma were assessed. Morning and evening predose FEV 1 values (recorded at each clinic visit) also were assessed. Because active treatment was administered in the evening for the once-daily treatment arms, morning PEF and FEV 1 represented assessments halfway through the oncedaily dosing interval.
Caregiver and Physician Global Assessments
At the end of the study, physicians and caregivers assessed the patients' overall level of asthma control by using a 5-point scale 8 in response to 2 questions: (1) How would you evaluate your patient's symptoms or child's health now versus at randomization (possible responses included "a great deal better," "somewhat better," "unchanged," "somewhat worse" and "a great deal worse")? and (2) How would you evaluate your ability to manage your patient's/ child's asthma (possible responses included "a great deal easier," "somewhat easier," "unchanged," "somewhat more difficult," and a "great deal more difficult").
Health-Related Quality of Life
Health-related quality of life was assessed by using the validated standardized Pediatric Asthma Quality of Life Questionnaire (PAQLQ [S] ) and Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ), 9, 10 which were completed by patients aged 7 years or older or their caregivers at screening and at all subsequent clinic visits. Both questionnaires were scored on a 7-point scale (1 [greatest possible impairment] to 7 [least impairment]). The minimal important difference was prespecified as a change in the overall or domain scores of Ն0.5 points on the 7-point scale. 
FIGURE 1
Study design. Patients who were receiving budesonide/formoterol pMDI twice daily were administered treatment in the morning and evening, whereas patients who were receiving once-daily treatments were administered placebo pMDI in the morning and active product in the evening using identical delivery devices to maintain study blinding. BUD indicates budesonide; FM, formoterol; bid, twice daily; R, randomization; qd, once daily. 
Safety Evaluations
Safety was evaluated on the basis of adverse events (AEs), laboratory evaluations, 24-hour urinary cortisol level, electrocardiograms, and physical examinations. An asthma-related AE (symptom or sign such as wheeze, cough, chest tightness, dyspnea, breathlessness, and phlegm) was to be recorded as an AE when it was serious, resulted in the patient discontinuing the study, was new to the patient, or was not consistent with the patient's preexisting asthma history. For each AE, the study investigator was to assess whether it was caused by the study medication by responding yes or no to the question, "Do you consider that there is reasonable possibility that the event may have been caused by the drug?" Blood specimens for chemistry and hematology were obtained, and 12-lead electrocardiograms were performed before dosing at screening and at the end of treatment. Twenty-four-hour urine samples for urinary free-cortisol analysis were collected Յ1 week after the screening visit and Յ1 week before the final clinic visit.
Statistical Analyses
The efficacy-analysis population included all patients in the safetyanalysis population (randomly assigned patients who received Ն1 dose of study medication) who completed Ն1 evening PEF diary entry after random assignment. The study was designed with a sample size of 540 subjects (180 per treatment group) to provide 88% power to test the null hypothesis that the mean difference between treatments in change from baseline in evening PEF was 0 L/minute versus the alternative of 10 L/minute (assuming a population SD of 30.0 L/minute and 5% type I error rate). The primary comparison for all variables was budesonide/formoterol pMDI 160/9 g versus budesonide pMDI 160 g, both administered once daily; the secondary comparison was the once-daily treatments versus budesonide/formoterol via pMDI 160/18 g (total daily dose) administered twice daily. All statistical comparisons were 2-sided tests, and P Յ .05 was considered significant.
Analysis of covariance (ANCOVA) was used to assess treatment differences in numeric variables while adjusting for center, treatment, age strata, and baseline; results are presented as least-squares mean differences with associated 95% confidence intervals and P values. The percentages of patients who had Ն1 predefined event of worsening asthma or were withdrawn because of predefined criteria for worsening asthma were compared between treatment groups by using the Cochran-Mantel-Haenszel (CMH) test while adjusting for age strata. Potential differences in treatment effects according to age (6 -11 or 12-15 years) were evaluated by adding the age strata-by-treatment interaction term to the ANCOVA models for evening PEF and evening predose FEV 1 . The percentages of physicians and caregivers who reported positive responses (top 2 response categories) on the global assessment questions were compared between groups by using a CMH test while adjusting for age strata. Data on AEs were summarized descriptively. Numerical safety variables were analyzed with ANCOVA models to detect differences in mean effects and with graphical and shift-table methodology to detect outliers.
RESULTS
Of the 719 patients who entered the run-in period, 522 were randomly assigned to receive study treatment (Fig  2) . The most common reason for withdrawal during the run-in period was failure to meet the entry criteria (135 
Efficacy
Pulmonary-Function Variables
Both budesonide/formoterol pMDI dosing regimens maintained evening PEF significantly more effectively than once-daily budesonide pMDI dosing (P Յ .027 for both) ( Table 3) . During the 12-week randomized treatment period, mean evening PEF values steadily improved from baseline values with twice-daily budesonide/formoterol pMDI, whereas they were maintained at the baseline level with once-daily budesonide/formoterol pMDI (Fig 3) . However, mean changes in evening PEF from baseline to the treatment-period average were not significantly different between the once-and twice-daily budesonide/formoterol pMDI groups (Table 3) . Evening predose FEV 1 improved from baseline values with twice-daily budesonide/formoterol pMDI and decreased with once-daily budesonide/formoterol pMDI and budesonide pMDI (P Յ .011 for twice-daily budesonide/formoterol pMDI versus both once-daily treatments) (Table 3) ; differences between the once-daily budesonide/formoterol pMDI and budesonide pMDI treatments were not significant. For both evening PEF and evening predose FEV 1 , there was no evidence of a differe568ential effect of treatment across age groups (P ϭ .713 and .290 for interaction test, respectively).
For morning PEF and morning predose FEV 1 , both budesonide/formoterol pMDI dosing regimens were significantly more effective than once-daily budesonide pMDI dosing (P Յ .010), and there were no significant differences noted between the budesonide/ formoterol pMDI groups (Table 3) . Morning PEF was well maintained during the randomized treatment period with both budesonide/formoterol pMDI dosing regimens; improvement from baseline values was observed for twice-daily budesonide/formoterol pMDI (Fig 4) .
Asthma-Control Variables
For daytime and nighttime asthma symptoms, symptom-free days, awakeningfree nights, and asthma-control days, the level of asthma control established during the run-in period was well maintained in all treatment groups, and there were no significant between-group differences observed (Table 4) . Compared with once-daily budesonide pMDI, treatment with twice-daily budesonide/formoterol pMDI resulted in significantly less daytime and nighttime rescue-medication use and more rescue-medication-free days (P Յ .023). Daytime rescue-medication use increased and rescue-medication-free days decreased with once-daily versus twice-daily budesonide/formoterol pMDI (P Յ .039).
The percentages of patients who experienced worsening asthma or were withdrawn from the study because of worsening asthma (on the basis of predefined criteria) were significantly lower with twice-daily budesonide/formoterol pMDI versus once-daily budesonide pMDI and once-daily budesonide/formoterol pMDI (P Յ .036) ( Table 4) . In children aged 6 to 11 years, the percentage of 
FIGURE 2
Patient disposition. a Because of randomization within each age stratum at each study center using balanced blocks of size 3 (1:1:1), imbalances between treatment groups in the overall number of randomly assigned patients occurred. b One patient was randomly assigned but did not receive study medication. BUD indicates budesonide; FM, formoterol; bid, twice daily; qd, once daily. patients with Ն1 predefined event of worsening asthma was lower with twice-daily budesonide/formoterol pMDI (7.5%) than with once-daily budesonide pMDI (18.6%) or once-daily budesonide/formoterol pMDI (24.8%); in patients aged 12 to 15 years, the percentages were similar across treatment groups (9.5%, 9.1%, and 7.8%, respectively).
Global Assessments
The percentage of caregivers whose responses indicated improvements in their child's asthma symptoms or the ease of asthma management since the randomization visit was similar across treatment groups (56.7%-60.4% for both questions). Similar results were observed for comparisons of the percentage of physicians whose responses indicated improvements in the patient's asthma symptoms (70.0%-77.8%). However, a significantly greater percentage of physicians' responses indicated improvements in the ease of asthma management since the randomization visit for patients who were receiving twice-daily budesonide/formoterol pMDI versus those who were receiving once-daily budesonide pMDI (75.0% vs 
FIGURE 3
Mean changes from baseline in evening PEF during the 12-week study, using last-observation-carried-forward methodology for early terminations. BUD indicates budesonide; FM, formoterol; bid, twice daily; qd, once daily.
64.4%; P ϭ .035) but not those receiving once-daily budesonide/formoterol pMDI (70.4%; P ϭ .362).
Health-Related Quality of Life
Health-related quality of life and caregiver burden, which were based on the PAQLQ(S) and PACQLQ, respectively, were stable at baseline and well maintained during the randomized study period in all treatment groups (see Supplemental Table 6 ). Neither the magnitude of mean changes within each treatment group nor the magnitude of mean differences between treatment groups was considered clinically meaningful according to the predefined minimal important difference of 0.5 for any of the PAQLQ(S) or PACQLQ overall or domain scores.
Safety
All treatments were generally well tolerated. Most AEs were of mild (72%) to moderate (25%) intensity. The incidence of overall AEs was similar across the treatment groups (Table 5). The incidence of AEs judged by the investigator to be related to study medication was low and similar across treatment groups; the most common AEs were oral candidiasis (1.3%), headache (0.4%), and pharyngolaryngeal pain (0.4%). Six patients experienced serious AEs during the randomized treatment period that were not considered related to study medication by the investigators: 2 in the twice-daily budesonide/formoterol pMDI group (abdominal pain and asthma), 3 in the once-daily budesonide/formoterol pMDI group (influenza [n ϭ 1] and asthma [n ϭ 2]), and 1 in the once-daily budesonide pMDI group (asthma). Eight patients discontinued the study because of an AE: 3 in the twice-daily budesonide/formoterol pMDI group (asthma [n ϭ 2] and influenza [n ϭ 1]), 4 in the oncedaily budesonide/formoterol pMDI group (asthma [n ϭ 2], influenza [n ϭ 1], and face injury/facial bones fracture [n ϭ 1]), and 1 in the budesonide pMDI group (asthma). Only 1 discontinuation attributable to an AE, which occurred in the twice-daily budesonide/ formoterol pMDI group (influenza), was considered by the investigator to be related to the study medication.
There were no clinically significant findings for laboratory assessments, electrocardiograms, vital signs, 24-hour urinary cortisol level, or physical examination in any treatment group. Results for serum glucose, serum potassium, electrocardiogram, and 24-hour urinary cortisol measures are presented in Supplemental Table 7 and Supplemental Table 8 . No clear differences between treatment groups with respect to outliers in urinary cortisol level were observed.
DISCUSSION
Better maintenance of pulmonary function occurred during the 12-week treatment period with once-daily budesonide/formoterol pMDI versus once-daily budesonide pMDI for most variables (primary objective), including evening PEF (primary variable), which was timed to coincide with the end of the 24-hour once-daily dosing interval. These experimental results suggest that formoterol may contribute clinically beneficial effects for at least 24 hours after dosing when administered in combination with budesonide. Similarly, findings from previous studies revealed a measurable bronchodilatory effect 24 hours after dosing of budesonide/formoterol via DPI in adults with asthma. 12, 13 It should be noted that, in contrast to the pulmonary-function results, no significant differences were observed between the once-daily budesonide/ formoterol pMDI and once-daily budesonide pMDI groups for measures of asthma symptoms and control. Health- 
FIGURE 4
Mean changes from baseline in morning PEF during the 12-week study, using last-observation-carried-forward methodology for early terminations. BUD indicates budesonide; FM, formoterol; bid, twice daily; qd, once daily.
related quality of life, as assessed by the PAQLQ(S) and PACQLQ, also was well maintained in both the twice-daily and once-daily treatment groups during our study, and no clinically meaningful changes or differences between the treatment groups were observed. The asthma-control results contrast with those reported by Bisgaard et al, 2 in which significantly better asthma control was observed with once-daily budesonide/formoterol DPI compared with a fourfold higher dose of oncedaily budesonide DPI in children with asthma. These contrasting results are potentially explained by differences in the run-in period that resulted in patients with more severe baseline asthma symptoms and greater margins for improvement in the study by Bisgaard et al 2 versus those in our study.
Twice-daily budesonide/formoterol pMDI produced significantly better results for all pulmonary-function variables versus once-daily budesonide pMDI. These results are consistent with those reported by Tal et al, 14 in which similar asthma control and better pulmonary function were observed with twice-daily budesonide/formoterol versus twice-daily budesonide alone at the same daily budesonide dose in children and adolescents. In our study, the results for asthma worsening (based on predefined criteria) and rescuemedication use significantly favored twice-daily budesonide/formoterol pMDI versus once-daily budesonide pMDI. Similarly, Kerwin et al, 5 reported significantly better asthma control for twicedaily budesonide/formoterol pMDI (320/ 18 g daily) compared with once-daily budesonide pMDI (320 g daily) in patients with asthma aged Ն12 years. In contrast to those from the study by Kerwin et al, the results of most other asthma-control measures in our study were similar between the twice-daily budesonide/formoterol pMDI and oncedaily budesonide pMDI groups. These different results may be related to differences in asthma severity between the patient populations, as evidenced by the deterioration in asthma control observed with once-daily budesonide pMDI in the study by Kerwin et al 5 versus the maintenance of asthma control in all treatment groups in our study.
To identify the minimum medication necessary to maintain control, current asthma guidelines recommend a step down in pharmacologic therapy once asthma control is achieved. 1 These recommendations stem from potential adverse effects that have been described for both ICS and LABA components. 1, 15 In our study and the study by Kerwin et al, 5 patients were stabilized on twice-daily budesonide/formoterol via pMDI, which corresponds with step 3 of the current asthma guidelines, 1 before stepping down to once-daily ICS or ICS/LABA treatment. In our study, significantly better results were observed with twice-daily versus oncedaily budesonide/formoterol pMDI for evening predose FEV 1 , daytime rescuemedication use, rescue-medicationfree days, and worsening asthma. Differences between the 2 budesonide/ formoterol pMDI dosing regimens were more apparent for variables assessed at the end of the 24-hour oncedaily dosing interval, and no safety benefits were observed with oncedaily versus twice-daily dosing regimens. Similar results were seen by Kerwin et al, who reported significantly better outcomes for twice-daily dosing. 5 Taken together, the results of these studies suggest that in patients appropriate for treatment with combination therapy, stepping down to oncedaily ICS/LABA or once-daily ICS alone at the doses studied does not confer additional safety advantages and may lead to decreased asthma control relative to continuation on twice-daily ICS/LABA maintenance therapy.
CONCLUSIONS
Once-daily dosing of budesonide/formoterol pMDI resulted in significantly better efficacy versus oncedaily budesonide pMDI for evening PEF (primary variable) and most other pulmonary-function variables in this population of children and adolescents with persistent asthma previously stabilized with budesonide/formoterol via pMDI twice daily. However, continued maintenance with twice-daily budesonide/ formoterol (160/18 g daily) pMDI produced clinical benefits relative to once-daily budesonide/formoterol (160/9 g daily) pMDI, administered at half the daily formoterol dose, for some pulmonary-function and asthma-control variables measured at the end of the 24-hour once-daily dosing interval. Safety profiles were similar among the treatments. Overall, these results suggest that for children and adolescents determined to be appropriate candidates for ICS/LABA combination therapy, 
